6. North America I.V. Iron Drug Market: Growth and Forecast
6.1. North America I.V. Iron Drug Market, By Value (2012-2016)
6.2. North America I.V. Iron Drug Market, By Value (2017-2022)
6.3. North America I.V. Iron Drug & Market - By Therapeutic Application, By Value
6.3.1. I.V. Iron Drug, By Value, % (2016)
6.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
6.4. North America I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
6.4.1. Nephrology, By Value (2012-2022)
6.4.2. Gynecology & Obstetrics, By Value (2012-2022)
6.4.3. Gastroenterology, By Value (2012-2022)
6.4.4. Oncology, By Value (2012-2022)
6.4.5. Cardiology, By Value (2012-2022)
6.4.6. Others, By Value (2012-2022)
6.5. North America I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
6.5.1. Ferric carboxymaltose, By Value (2012-2022)
6.5.2. Iron Sucrose, By Value (2012-2022)
6.5.3. Iron Dextran
6.5.4. Others
6.6. North America I.V. Iron Drug Market: Country Analysis (U.S., Canada)
6.6.1. North America I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
6.6.2. North America I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)
6.7. U.S. I.V. Iron Drug Market: Growth and Forecast
6.7.1. U.S. I.V. Iron Drug Market, By Value (2012-2016)
6.7.2. U.S. I.V. Iron Drug Market, By Value (2017-2022)
6.8. U.S. I.V. Iron Drug & Market - By Therapeutic Application, By Value
6.8.1. I.V. Iron Drug, By Value, % (2016)
6.8.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
6.9. U.S. I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
6.9.1. Nephrology, By Value (2012-2022)
6.9.2. Gynecology & Obstetrics, By Value (2012-2022)
6.9.3. Gastroenterology, By Value (2012-2022)
6.9.4. Oncology, By Value (2012-2022)
6.9.5. Cardiology, By Value (2012-2022)
6.9.6. Others, By Value (2012-2022)
6.10. Canada I.V. Iron Drug Market: Growth and Forecast
6.10.1. Canada I.V. Iron Drug Market, By Value (2012-2016)
6.10.2. Canada I.V. Iron Drug Market, By Value (2017-2022)
6.11. Canada I.V. Iron Drug & Market - By Therapeutic Application, By Value
6.11.1. I.V. Iron Drug, By Value, % (2016)
6.11.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
6.12. Canada I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
6.12.1. Nephrology, By Value (2012-2022)
6.12.2. Gynecology & Obstetrics, By Value (2012-2022)
6.12.3. Gastroenterology, By Value (2012-2022)
6.12.4. Oncology, By Value (2012-2022)
6.12.5. Cardiology, By Value (2012-2022)
6.12.6. Others, By Value (2012-2022)
7. Europe I.V. Iron Drug Market: Growth and Forecast
7.1. I.V. Iron Drug Market, By Value (2012-2016)
7.2. I.V. Iron Drug Market, By Value (2017-2022)
7.3. Europe I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.3.1. I.V. Iron Drug, By Value, % (2016)
7.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
7.4. Europe I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.4.1. Nephrology, By Value (2012-2022)
7.4.2. Gynecology & Obstetrics, By Value (2012-2022)
7.4.3. Gastroenterology, By Value (2012-2022)
7.4.4. Oncology, By Value (2012-2022)
7.4.5. Cardiology, By Value (2012-2022)
7.4.6. Others, By Value (2012-2022)
7.5. Europe I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
7.5.1. Ferric carboxymaltose, By Value (2012-2022)
7.5.2. Iron Sucrose, By Value (2012-2022)
7.5.3. Iron Dextran
7.5.4. Others
7.6. Europe I.V. Iron Drug Market: Country Analysis (U.K., Germany, France, Rest of Europe)
7.6.1. Europe I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
7.6.2. Europe I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)
7.7. U.K. I.V. Iron Drug Market: Growth and Forecast
7.7.1. U.K. I.V. Iron Drug Market, By Value (2012-2016)
7.7.2. U.K. I.V. Iron Drug Market, By Value (2017-2022)
7.8. U.K. I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.8.1. I.V. Iron Drug, By Value, % (2016)
7.8.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
7.9. U.K. I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.9.1. Nephrology, By Value (2012-2022)
7.9.2. Gynecology & Obstetrics, By Value (2012-2022)
7.9.3. Gastroenterology, By Value (2012-2022)
7.9.4. Oncology, By Value (2012-2022)
7.9.5. Cardiology, By Value (2012-2022)
7.9.6. Others, By Value (2012-2022)
7.10. Germany I.V. Iron Drug Market: Growth and Forecast
7.10.1. Germany I.V. Iron Drug Market, By Value (2012-2016)
7.10.2. Germany I.V. Iron Drug Market, By Value (2017-2022)
7.11. Germany I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.11.1. I.V. Iron Drug, By Value, % (2016)
7.11.2 I.V. Iron Drug, By Value, % (Forecast 2022F)
7.12. Germany I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.12.1. Nephrology, By Value (2012-2022)
7.12.2. Gynecology & Obstetrics, By Value (2012-2022)
7.12.3. Gastroenterology, By Value (2012-2022)
7.12.4. Oncology, By Value (2012-2022)
7.12.5. Cardiology, By Value (2012-2022)
7.12.6. Others, By Value (2012-2022)
7.13. France I.V. Iron Drug Market: Growth and Forecast
7.13.1. France I.V. Iron Drug Market, By Value (2012-2016)
7.13.2. France I.V. Iron Drug Market, By Value (2017-2022)
7.14. France I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.14.1. I.V. Iron Drug, By Value, % (2016)
7.14.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
7.15. France I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.15.1. Nephrology, By Value (2012-2022)
7.15.2. Gynecology & Obstetrics, By Value (2012-2022)
7.15.3. Gastroenterology, By Value (2012-2022)
7.15.4. Oncology, By Value (2012-2022)
7.15.5. Cardiology, By Value (2012-2022)
7.15.6. Others, By Value (2012-2022)
7.16. Rest of Europe I.V. Iron Drug Market: Growth and Forecast
7.16.1. Rest of Europe I.V. Iron Drug Market, By Value (2012-2016)
7.16.2. Rest of Europe I.V. Iron Drug Market, By Value (2017-2022)
8. Asia Pacific I.V. Iron Drug Market: Growth and Forecast
8.1. I.V. Iron Drug Market, By Value (2012-2016)
8.2. I.V. Iron Drug Market, By Value (2017-2022)
8.3. Asia Pacific I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.3.1. I.V. Iron Drug, By Value, % (2016)
8.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.4. Asia Pacific I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.4.1. Nephrology, By Value (2012-2022)
8.4.2. Gynecology & Obstetrics, By Value (2012-2022)
8.4.3. Gastroenterology, By Value (2012-2022)
8.4.4. Oncology, By Value (2012-2022)
8.4.5. Cardiology, By Value (2012-2022)
8.4.6. Others, By Value (2012-2022)
8.5. Asia Pacific I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
8.5.1. Ferric carboxymaltose, By Value (2012-2022)
8.5.2. Iron Sucrose, By Value (2012-2022)
8.5.3. Iron Dextran
8.5.4. Others
8.6. Asia Pacific I.V. Iron Drug Market: Country Analysis (Japan, China, India, Rest of Asia-Pacific)
8.6.1. Asia Pacific I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
8.6.2. Asia Pacific I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)
8.7. Japan I.V. Iron Drug Market: Growth and Forecast
8.7.1. Japan I.V. Iron Drug Market, By Value (2012-2016)
8.7.2. Japan I.V. Iron Drug Market, By Value (2017-2022)
8.8. Japan I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.8.1. I.V. Iron Drug, By Value, % (2016)
8.8.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.9. Japan I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.9.1. Nephrology, By Value (2012-2022)
8.9.2. Gynecology & Obstetrics, By Value (2012-2022)
8.9.3. Gastroenterology, By Value (2012-2022)
8.9.4. Oncology, By Value (2012-2022)
8.9.5. Cardiology, By Value (2012-2022)
8.9.6. Others, By Value (2012-2022)
8.10. China I.V. Iron Drug Market: Growth and Forecast
8.10.1. China I.V. Iron Drug Market, By Value (2012-2016)
8.10.2. China I.V. Iron Drug Market, By Value (2017-2022)
8.11. China I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.11.1. I.V. Iron Drug, By Value, % (2016)
8.11.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.12. China I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.12.1. Nephrology, By Value (2012-2022)
8.12.2. Gynecology & Obstetrics, By Value (2012-2022)
8.12.3. Gastroenterology, By Value (2012-2022)
8.12.4. Oncology, By Value (2012-2022)
8.12.5. Cardiology, By Value (2012-2022)
8.12.6. Others, By Value (2012-2022)
8.13. India I.V. Iron Drug Market: Growth and Forecast
8.13.1. India I.V. Iron Drug Market, By Value (2012-2016)
8.13.2. India I.V. Iron Drug Market, By Value (2017-2022)
8.14. India I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.14.1. I.V. Iron Drug, By Value, % (2016)
8.14.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.15. India I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.15.1. Nephrology, By Value (2012-2022)
8.15.2. Gynecology & Obstetrics, By Value (2012-2022)
8.15.3. Gastroenterology, By Value (2012-2022)
8.15.4. Oncology, By Value (2012-2022)
8.15.5. Cardiology, By Value (2012-2022)
8.15.6. Others, By Value (2012-2022)
8.16. Rest of Asia Pacific I.V. Iron Drug Market: Growth and Forecast
8.16.1. Rest of Asia Pacific I.V. Iron Drug Market, By Value (2012-2016)
8.16.2. Rest of Asia Pacific I.V. Iron Drug Market, By Value (2017-2022)
9. ROW I.V. Iron Drug Market: Growth and Forecast
9.1. I.V. Iron Drug Market, By Value (2012-2016)
9.2. I.V. Iron Drug Market, By Value (2017-2022)
9.3. ROW I.V. Iron Drug & Market - By Therapeutic Application, By Value
9.3.1. I.V. Iron Drug, By Value, % (2016)
9.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
9.4. ROW I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
9.4.1. Nephrology, By Value (2012-2022)
9.4.2. Gynecology & Obstetrics, By Value (2012-2022)
9.4.3. Gastroenterology, By Value (2012-2022)
9.4.4. Oncology, By Value (2012-2022)
9.4.5. Cardiology, By Value (2012-2022)
9.4.6. Others, By Value (2012-2022)
9.5. ROW I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
9.5.1. Ferric carboxymaltose, By Value (2012-2022)
9.5.2. Iron Sucrose, By Value (2012-2022)
9.5.3. Iron Dextran
9.5.4. Others
9.6. ROW I.V. Iron Drug Market: Country Analysis (Brazil, South Africa)
9.6.1. ROW I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
9.6.2. ROW I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)
9.7. Brazil I.V. Iron Drug Market: Growth and Forecast
9.7.1. Brazil I.V. Iron Drug Market, By Value (2012-2016)
9.7.2. Brazil I.V. Iron Drug Market, By Value (2017-2022)
9.8. South Africa I.V. Iron Drug Market: Growth and Forecast
9.8.1. South Africa I.V. Iron Drug Market, By Value (2012-2016)
9.8.2. South Africa I.V. Iron Drug Market, By Value (2017-2022)
List of Figures
Figure 1: Causes of premature (under age 70) NCD mortality, 2017 (%)
Figure 2: Global I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 3: World Population 65 Years & Above (% of Total), 2012-2016
Figure 4: Life Expectancy at birth rate (Years), 2012-2015
Figure 5: Global Life expectancy at birth, total (years) 2012 -2015
Figure 6: World Female Population, 2012-2016
Figure 7: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 8: Global Potential Patients Numbers, All Indications 2017 (In Million)
Figure 9: Global I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 10: Global I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 11: Global I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 12: Global I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 13: Worldwide Dialysis Patients, Numbers (In Million), 2010, 2015, 2020
Figure 14: Global I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)
Figure 15: Global I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)
Figure 16: North America I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 17: North America Population 65 Years & Above (% of Total), 2012-2016
Figure 18: North America Life Expectancy at birth rate (Years), 2012-2015
Figure 19: North America Women Population, 2012-2016
Figure 20: North America, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 21: Population aged 65 & above, 2012-2016 (% of total)
Figure 22: North America I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 23: North America I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 24: North America I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 25: North America I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 26: North America I.V. Iron Drug Market - By Product Type, By Value, 2012-2022 (USD Million)
Figure 27: North America I.V. Iron Drug Market, Country Share, 2016 (% of Total)
Figure 28: North America I.V. Iron Drug Market, Country Share, 2022 (% of Total)
Figure 29: U.S. I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 30: U.S. Population 65 Years & Above (% of Total), 2012-2016
Figure 31: U.S. Life Expectancy at birth rate (Years), 2012-2015
Figure 32: U.S. Women Population, 2012-2016
Figure 33: U.S. Per Capita Healthcare Expenditure, 2012-2014 (In Trillion)
Figure 34: United States I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)
Figure 35: U.S. I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 36: U.S. I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 37: U.S. I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 38: Canada I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 39: Canada Population 65 Years & Above (% of Total), 2012-2016
Figure 40: Canada Life Expectancy at birth rate (Years), 2012-2015
Figure 41: Canada Women Population, 2012-2016
Figure 42: End Stage Kidney Disease patients by Age group, 2012-2015 (Numbers)
Figure 43: Prevalent end-stage kidney disease patients by age group, Canada (excluding Quebec), 2012-2015 (Numbers)
Figure 44: Prevalence rate for patients on dialysis (Excluding Quebec), 2012-2015
Figure 45: Prevalent rate for patients on dialysis or with a functioning transplant in Canada (excluding Quebec), 2012-2015
Figure 46: Canada I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 47: Canada I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 48: Canada I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 49: Europe I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 50: European Union Population 65 Years & Above (% of Total), 2012-2016
Figure 51: European Union Life Expectancy at birth rate (Years), 2012-2015
Figure 52: European Union Women Population, 2012-2016
Figure 53: European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 54: European Potential Patients Numbers, All Indications 2017 (In Million)
Figure 55: Europe I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 56: Europe I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 57: Europe I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 58: Europe I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 59: Europe I.V. Iron Drug Market - By Product Type, By Value, 2012-2022, (USD Million)
Figure 60: Europe I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)
Figure 61: Europe I.V. Iron Drug Market, Country Share, 2016 (% of Total)
Figure 62: Europe I.V. Iron Drug Market, Country Share, 2022 (% of Total)
Figure 63: U.K. I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 64: U.K. Population 65 Years & Above (% of Total), 2012-2016
Figure 65: U.K. Life Expectancy at birth rate (Years), 2012-2015
Figure 66: U.K. Women Population, 2012-2016
Figure 67: U.K., Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 68: U.K. I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 69: U.K. I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 70: U.K. I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 71: Germany I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 72: Germany Population 65 Years & Above (% of Total), 2012-2016
Figure 73: Germany Life Expectancy at birth rate (Years), 2012-2015
Figure 74: Germany Women Population, 2012-2016
Figure 75: Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD)
Figure 76: Germany I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 77: Germany I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 78: Germany I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 79: France I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 80: France Population 65 Years & Above (% of Total), 2012-2016
Figure 81: France Life Expectancy at birth rate (Years), 2012-2015
Figure 82: France Women Population, 2012-2016
Figure 83: France Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 84: France I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 85: France I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 86: France I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 87: Rest of Europe I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 88: Asia-Pacific I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 89: Asia-Pacific I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 90: Asia-Pacific I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 91: Asia-Pacific I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 92: Asia-Pacific I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 93: Asia-Pacific I.V. Iron Drug Market - By Product Type, By Value, 2012-2022 (USD Million)
Figure 94: Asia-Pacific I.V. Iron Drug Market, Country Share, 2016 (% of Total)
Figure 95: Asia-Pacific I.V. Iron Drug Market, Country Share, 2022 (% of Total)
Figure 96: Japan I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 97: Japan Population 65 Years & Above (% of Total), 2012-2016
Figure 98: Japan Life Expectancy at birth rate (Years), 2012-2015
Figure 99: Japan, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 100: Japan I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 101: Japan I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 102: Japan I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 103: China I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 104: China Population 65 Years & Above (% of Total), 2012-2016
Figure 105: China Life Expectancy at birth rate (Years), 2012-2015
Figure 106: China Women Population, 2012-2016
Figure 107: China Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 108: China I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 109: China I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 110: China I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 111: Registered Number Dialysis patients in China (In ten thousands), 2012-2016
Figure 112: India I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 113: India Population 65 Years & Above (% of Total), 2012-2016
Figure 114: India Life Expectancy at birth rate (Years), 2012-2015
Figure 115: India Women Population, 2012-2016
Figure 116: India Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 117: India I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 118: India I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 119: India I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 120: Rest of Asia-Pacific I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 121: ROW I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 122: ROW I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 123: ROW I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 124: ROW I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 125: ROW I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 126: ROW I.V. Iron Drug Market - By Product Type, By Value, 2012-2022 (USD Million)
Figure 127: ROW I.V. Iron Drug Market, Country Share, 2016 (% of Total)
Figure 128: ROW I.V. Iron Drug Market, Country Share, 2022 (% of Total)
Figure 129: Brazil I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 130: Brazil Population 65 Years & Above (% of Total), 2012-2016
Figure 131: Brazil Life Expectancy at birth rate (Years), 2012-2015
Figure 132: Brazil Women Population, 2012-2016
Figure 133: Brazil, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 134: South Africa I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 135: South Africa Population 65 Years & Above (% of Total), 2012-2016
Figure 136: South Africa Life Expectancy at birth rate (Years), 2012-2015
Figure 137: South Africa Women Population, 2012-2016
Figure 138: South Africa Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 139: Percentage aged 60 years and over, (2000, 2015, 2030, 2050)
Figure 140: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 141: Global Dialysis Patients, By Dialysis, 2016, (% Share)
Figure 142: Global Dialysis Patients, 2012 -2016, Million
Figure 143: Global Life expectancy at birth, total (years) 1990-2100
Figure 144: Net Sales, By Business Unit, 2016 (%)
Figure 145: Net Sales, By Region, 2016 (%)
Figure 146: Revenue, 2013-2016 (USD Million)
Figure 147: AMAG Pharmaceuticals, Inc. Revenue (USD Million) 2012-2016
Figure 148: Net Sales, By Business Unit, 2016 (%)
Figure 149: AMAG Pharmaceuticals, Inc. Revenue (USD Million) 2014-2016
Figure 150: Net Sales, By Business Unit, 2016 (%)
Figure 151: Daichi Sankyo Company Ltd. Revenue, By Business segment, 2016 (%)
Figure 152: Daichi Sankyo Company Ltd. JAPAN BUSINESS, By Revenues, By Business segment, 2016 (%)
Figure 153: Daichi Sankyo Company Ltd.Revenue (USD Million) 2012-2016
Figure 154: Nippon Shinyaku Co. Ltd. By Revenues, By Business segment, % Share Year Ending March 31st 2017 (%)
Figure 155: Nippon Shinyaku Co. Ltd. Revenue (USD Million) 2013-2017, Year Ending March 31st 2017
Figure 156: Nippon Shinyaku Co. Ltd. Revenue, By Geography, % Share, Year Ending March 31st 2017
Figure 157: Nippon Shinyaku Co. Ltd. R & D Expenses, 2016 (%)
Figure 158: Sanofi Revenue, By Business segment, 2016 (%)
Figure 159: Sanofi BUSINESS, By, Revenues, By Business segment, 2016 (%)
Figure 160: Sanofi Revenue (USD Million) 2012-2016